The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Ascending dose trials of the safety and tolerability of Toca 511, a retroviral replicating vector encoding cytosine deaminase, in patients with recurrent high-grade glioma.
Daniel Pertschuk
Employment or Leadership Position - Tocagen
Stock Ownership - Tocagen
Timothy Francis Cloughesy
Research Funding - Tocagen
Susan Marina Chang
Research Funding - Tocagen
Manish K. Aghi
Honoraria - Tocagen
Research Funding - Tocagen
Michael A. Vogelbaum
Research Funding - Tocagen
Linda M. Liau
Research Funding - Tocagen
Bob B. Shafa
Research Funding - Tocagen
William H. Yong
Research Funding - Tocagen
Clark Chen
Research Funding - Tocagen
Santosh Kesari
Research Funding - Tocagen
Carlos E. Ibanez
Employment or Leadership Position - Tocagen
Stock Ownership - Tocagen
Omar D. Perez
Employment or Leadership Position - Tocagen
Stock Ownership - Tocagen
Joan M. Robbins
Employment or Leadership Position - Tocagen
Stock Ownership - Tocagen
Douglas J. Jolly
Employment or Leadership Position - Tocagen
Stock Ownership - Tocagen
Harry E. Gruber
Employment or Leadership Position - Tocagen
Stock Ownership - Tocagen